Loading
A phase 1/2 trial of Talquetamab, Teclistamab in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT04586426 by Janssen Research & Development, LLC, with 228 participants enrolled, started 2020-12-15 and due to reach its primary completion in 2025-03-18. Interventions recorded: Talquetamab, Teclistamab. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Shares Teclistamab, Relapsed or refractory multiple myeloma, Johnson & Johnson, T-cell engagers (bispecific).
Shares Teclistamab, Relapsed or refractory multiple myeloma, Johnson & Johnson, T-cell engagers (bispecific).
Shares Talquetamab, Relapsed or refractory multiple myeloma, Johnson & Johnson, T-cell engagers (bispecific).
Shares Talquetamab, Teclistamab, Johnson & Johnson, T-cell engagers (bispecific).
Shares Talquetamab, Relapsed or refractory multiple myeloma, Johnson & Johnson, T-cell engagers (bispecific).
Shares Talquetamab, Teclistamab, Johnson & Johnson, T-cell engagers (bispecific).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/